CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
August 2020—Illumina announced that the FDA issued an emergency use authorization for the Illumina COVIDSeq test, a high-throughput, sequencing-based, in vitro diagnostic workflow enabling the detection of SARS-CoV-2.
COVIDSeq uses upper respiratory specimens, including a nasopharyngeal or oropharyngeal swab, and delivers sample receipt to result in 24 hours using the NovaSeq 6000 sequencing system. The differentiated diagnostic design includes 98 amplicons that target the full SARS-CoV-2 genome.
Pages: 1 2